Search research articles
Contact Us
Filters
Showing results (81-90 of 418) with videos related to
Page
of 42
Sort By:
The New England Journal of Medicine
|
January 21, 2016
More on PML in Patients Treated with Dimethyl Fumarate
Kristian Reich, Hans-Peter Hartung, Mark Lebwohl
Journal of Drugs in Dermatology : JDD
|
March 4, 2026
Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics
William C Lau, Benjamin Gerstein, Mark Lebwohl
Pediatric Health, Medicine and Therapeutics
|
February 2, 2018
Efficacy and safety of ustekinumab in adolescents
Roselyn Kellen, Nanette B Silverberg, Mark Lebwohl
Journal of the American Academy of Dermatology
|
August 1, 2020
Reply to research letter
Ryan Rivera-Oyola, Merav Koschitzky, Mark Lebwohl
The Journal of Clinical and Aesthetic Dermatology
|
April 3, 2012
Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis
Mark Lebwohl, Norman Preston, Ronald W Gottschalk
Journal of Drugs in Dermatology : JDD
|
December 27, 2018
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy
Emil Tanghetti, Mark Lebwohl, Linda Stein Gold
Journal of Drugs in Dermatology : JDD
|
October 2, 2025
The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
William C Lau, Alexandra K Golant, Mark Lebwohl
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
June 24, 2004
The use of the 308-nm excimer laser for the treatment of vitiligo
Suhail M Hadi, James M Spencer, Mark Lebwohl
Journal of the American Academy of Dermatology
|
April 14, 2020
Reply to: "Biologics for psoriasis during COVID-19 outbreak"
Dedee F Murrell, Ryan Rivera-Oyola, Mark Lebwohl
Journal of Drugs in Dermatology : JDD
|
December 2, 2025
More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis
John Koo, George Han, Mark Lebwohl, et al.
Page
of 42
Search research articles
Search
Showing results (81-90 of 418) with videos related to
Sort By:
Page
of 42
The New England Journal of Medicine
|
January 21, 2016
More on PML in Patients Treated with Dimethyl Fumarate
Kristian Reich, Hans-Peter Hartung, Mark Lebwohl
Journal of Drugs in Dermatology : JDD
|
March 4, 2026
Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics
William C Lau, Benjamin Gerstein, Mark Lebwohl
Pediatric Health, Medicine and Therapeutics
|
February 2, 2018
Efficacy and safety of ustekinumab in adolescents
Roselyn Kellen, Nanette B Silverberg, Mark Lebwohl
Journal of the American Academy of Dermatology
|
August 1, 2020
Reply to research letter
Ryan Rivera-Oyola, Merav Koschitzky, Mark Lebwohl
The Journal of Clinical and Aesthetic Dermatology
|
April 3, 2012
Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis
Mark Lebwohl, Norman Preston, Ronald W Gottschalk
Journal of Drugs in Dermatology : JDD
|
December 27, 2018
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy
Emil Tanghetti, Mark Lebwohl, Linda Stein Gold
Journal of Drugs in Dermatology : JDD
|
October 2, 2025
The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
William C Lau, Alexandra K Golant, Mark Lebwohl
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
June 24, 2004
The use of the 308-nm excimer laser for the treatment of vitiligo
Suhail M Hadi, James M Spencer, Mark Lebwohl
Journal of the American Academy of Dermatology
|
April 14, 2020
Reply to: "Biologics for psoriasis during COVID-19 outbreak"
Dedee F Murrell, Ryan Rivera-Oyola, Mark Lebwohl
Journal of Drugs in Dermatology : JDD
|
December 2, 2025
More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis
John Koo, George Han, Mark Lebwohl, et al.
Page
of 42